How This Evidence Evolved
HER2 Classification Evolution
From binary positive/negative to the HER2-low paradigm shift
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Standardized HER2 testing criteria
Disease-free survival
Disease-free survival at 5 years: AC-T 75%, AC-T plus trastuzumab 84%, TCH 81%
Follow-up studies, subgroup analyses, and real-world validation
PFS in all patients: trastuzumab deruxtecan 9.9 vs chemotherapy 5.1 months (HR 0.50, P<0.001)
PFS in HER2-low disease: trastuzumab deruxtecan 13.2 vs chemotherapy 8.1 months (HR 0.62, 95% CI 0.52–0.75)
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Landmark Trials in This Story
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Correlation of HER2 amplification with relapse and survival
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Standardized HER2 testing criteria
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Disease-free survival
Adjuvant trastuzumab in HER2-positive breast cancer.
Disease-free survival at 5 years: AC-T 75%, AC-T plus trastuzumab 84%, TCH 81%
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
PFS in all patients: trastuzumab deruxtecan 9.9 vs chemotherapy 5.1 months (HR 0.50, P<0.001)
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
PFS in HER2-low disease: trastuzumab deruxtecan 13.2 vs chemotherapy 8.1 months (HR 0.62, 95% CI 0.52–0.75)
Artificial Intelligence (AI)-Assisted Human Epidermal Growth Factor Receptor 2 (HER2) Scoring in Breast Cancer: Diagnostic Agreement and Understanding Discordance.
Reader agreement at slide review: without AI 79.8% vs with AI 88.6% (95% CIs 77.9–81.7 and 86.9–90.1)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.